

Articles

***N*-Phosphonacetyl-L-isoasparagine a Potent and Specific Inhibitor of *Escherichia coli* Aspartate Transcarbamoylase[†]**Joby Eldo,^{‡,||} James P. Cardia,^{‡,||} Elizabeth M. O'Day,[‡] Jiarong Xia,[‡] Hiro Tsuruta,[§] and Evan R. Kantrowitz^{*,‡}*Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts 02467-3808, and Stanford Synchrotron Radiation Laboratory, Stanford Linear Accelerator Center, MS 69, Stanford, California 94309-0210*

Received June 15, 2006

The synthesis of a new inhibitor, *N*-phosphonacetyl-L-isoasparagine (PALI), of *Escherichia coli* aspartate transcarbamoylase (ATCase) is reported, as well as structural studies of the enzyme•PALI complex. PALI was synthesized in 7 steps from β -benzyl L-aspartate. The K_D of PALI was 2 μ M. Kinetics and small-angle X-ray scattering experiments showed that PALI can induce the cooperative transition of ATCase from the T to the R state. The X-ray structure of the enzyme•PALI complex showed 22 hydrogen-bonding interactions between the enzyme and PALI. The kinetic characterization and crystal structure of the ATCase•PALI complex also provides detailed information regarding the importance of the α -carboxylate for the binding of the substrate aspartate.

Introduction

Aspartate transcarbamoylase (ATCase,^a EC 2.1.3.2) from *Escherichia coli* catalyzes the committed step in de novo pyrimidine nucleotide biosynthesis, the condensation of carbamoyl phosphate (CP), and L-aspartate to yield *N*-carbamoyl-L-aspartate and P_i. The binding of substrates is ordered where the binding of CP is required for the binding of Asp.¹ In *E. coli*, ATCase is allosterically regulated homotropically by Asp and heterotropically by the end products of the pyrimidine and purine pathways. CTP and UTP, the end products of the pyrimidine biosynthetic pathway, inhibit ATCase.² However, UTP only inhibits the enzyme in the presence of CTP.³ ATP, an end product of the purine biosynthetic pathway, activates the enzyme.²

N-phosphonacetyl-L-aspartate (PALA), a bisubstrate analogue of ATCase, inhibits both the *E. coli* and the mammalian enzymes.^{4,5} Because ATCase is involved in the biosynthesis of pyrimidine nucleotides, which are required for cell division, PALA has been tested as a potential anticancer agent. PALA was found to block the growth of colonic cancer cells, Lewis cell carcinoma, and melanoma, leading to clinical trials of PALA as an anticancer drug.^{6,7} As a means to produce even more effective inhibitors of ATCase, various modifications of PALA

have been synthesized.^{8,9} However, none have been found with significantly enhanced activity compared to PALA.⁸ Because of the large negative charge on PALA at physiological pH, attempts have been made to encapsulate it into liposomes for delivery.^{10,11}

E. coli ATCase is a dodecamer composed of six chains (M_r 34 000 each) grouped into two catalytic trimers and six chains (M_r 17 000 each) grouped into three regulatory dimers. Three active sites are located in the catalytic trimer, where each active site is shared between the adjacent catalytic chains. Each catalytic chain contains two structural domains, the carbamoyl phosphate (CP) domain (residues 1–135 and 292–310) and the aspartate (ASP) domain (residues 136–291), which contain the binding sites for CP and Asp, respectively. The regulatory chain is composed of two domains, the allosteric (AL) domain (residues 1–100) and the zinc (ZN) domain (residues 101–153), which contain the binding sites for nucleotides and zinc, respectively.

In *E. coli* ATCase, the binding of PALA induces large conformational changes in the enzyme from the low-activity, low-affinity T-state, to the high-activity, high-affinity R-state. Upon the binding of PALA, the enzyme undergoes a rotation of 10° and an expansion of 11 Å along the 3-fold axis, in addition, there is a 15° rotation of the regulatory dimers around their respective 2-fold axes.¹² Small-angle X-ray scattering (SAXS) experiments in solution also show an expansion of the enzyme upon the addition of PALA.¹³ The mechanism is ordered with CP binding before Asp and *N*-carbamoyl-L-aspartate leaving before P_i. Upon the binding of CP, local conformational changes occur, the 50s loop (residues 50–55) moves toward the CP molecule when compared to the T_{apo} structure, and the binding pocket for Asp is formed.¹⁴ The binding of Asp to the enzyme•CP complex induces the two domains of the catalytic chain to close, bringing both substrates into close proximity.¹⁴ The binding of PALA induces the same conformational change as do the natural substrates.¹³

The α -carboxylate of PALA interacts with the guanidinium group of Arg167 in the active site of ATCase. However, mutation of Arg167 to Gln does not effect the binding of PALA

* To whom correspondence should be addressed. E-mail: evan.kantrowitz@bc.edu. Tel.: 617-552-4558. Fax: 617-552-2705.

[†] Coordinates for the aspartate transcarbamoylase complex with *N*-phosphonacetyl-L-isoasparagine have been deposited in the Protein Data Bank (entry 2H3E).

[‡] Boston College.

[§] Stanford Synchrotron Radiation Laboratory.

^{||} Contributed equally to this work.

^a Abbreviations: ATCase, *Escherichia coli* aspartate transcarbamoylase; PALA, *N*-phosphonacetyl-L-aspartate; PALI, *N*-phosphonacetyl-L-isoasparagine or *N*-phosphonacetyl-L- α -asparagine; CP, carbamoyl phosphate; C1/C6, the two catalytic chains of ATCase in the asymmetric unit of the crystal; R1/R6, the two regulatory chains of ATCase in the asymmetric unit of the crystal; R_{PALA}, structure of the wild-type ATCase complexed with PALA (PDB entry 1D09); R_{PALI}, structure of the wild-type ATCase complexed with PALI; T_{apo}, structure of the wild-type ATCase in the T state (PDB entry 1ZA1); C chain, catalytic chain; R chain, regulatory chain; SAXS, small-angle X-ray scattering; R167Q, the mutant ATCase in which Arg167 of the catalytic chain has been replaced by Gln.




Figure 1. Scheme for the synthesis of PALI. (a) di-*tert*-butyl dicarbonate, NaHCO₃, H₂O/THF (1:1), rt, overnight; (b) (i) Et₃N, ethyl chloroformate, CH₂Cl₂/dioxane; (ii) 28% aq NH₃, rt, 4 h; (c) CH₂Cl₂/TFA (1:1), rt, 4 h; (d) chloroacetic anhydride, pyridine, CH₂Cl₂, rt, 4 h; (e) triethyl phosphite, 150 °C, 8 h; (f) trimethylsilyl bromide, acetonitrile, rt, overnight; (g) 10% Pd/C, H₂, THF/EtOH, rt, overnight.

to the enzyme. The charge interaction between Arg167 and the α -carboxylate led us to believe that a derivate of PALA with reduced charge could bind with similar affinity to the enzyme and induce the allosteric transition. To test this hypothesis, we synthesized the α -amide derivative of PALA, which would reduce the charge of the analogue and at the same time enhance its lipophilicity. Here we report the synthesis, inhibition kinetic data, and X-ray crystal structure of a derivative of PALA, *N*-phosphonacetyl-L-isoasparagine, PALI.

Results

Synthesis of *N*-Phosphonacetyl-L-isoasparagine (1, PALI).

PALI was synthesized from commercially available β -benzyl L-aspartate (98% ee; **2**) using modified literature procedures, as shown in Figure 1. After protecting the amino group using Boc chemistry, reaction of β -benzyl *N*-*tert*-butoxycarbonyl-L-aspartate (**3**) with ethyl chloroformate and aqueous ammonia afforded the amide (**4**). Then the TFA-mediated Boc deprotection (**5**) and subsequent *N*-acylation using chloroacetic anhydride and pyridine gave the β -benzyl *N*-chloroacetyl-L-isoaspariginatate (**6**) with a yield of 80%. Reaction of **6** with triethyl phosphite under reflux conditions afforded the corresponding phosphonate ester (**7**) in 95% yield. The β -benzyl *N*-phosphonacetyl-L-isoaspariginatate (**8**) was obtained in quantitative yield by the deprotection of phosphonate esters using trimethylsilyl bromide. Then the final benzyl ester was deprotected using 10% Pd on activated carbon in a H₂ atmosphere at room temperature affording *N*-phosphonacetyl-L-isoasparagine (**1**, PALI).

Binding of PALI to ATCase. As a result of the cooperative binding of aspartate and severe substrate inhibition, kinetic experiments to obtain K_I values for PALI were not performed with ATCase. Therefore, to measure the affinity of PALI for ATCase, a pyrene-labeled version of the ATCase holoenzyme was used.¹⁵ The fluorescence intensity of this pyrene-labeled enzyme is related to the fraction of the active sites filled. Dissociation constants of 0.69 μ M and 2.0 μ M were calculated for PALA and PALI, respectively. A comparison of the standard free energies of PALA and PALI reveals a difference ($|\Delta G^\circ_{\text{PALA}} - \Delta G^\circ_{\text{PALI}}|$) in energy of 1.0 kcal/mol, where $\Delta G^\circ = -RT \ln(1/K_D)$.

At a subsaturating concentration of Asp and saturating concentration of CP, addition of PALA dramatically increases the activity of ATCase. However, at higher concentrations of




Figure 2. Influence of PALA (○) and PALI (●) on the active site of ATCase. Colorimetric assays were carried out at 25 °C in 50 mM Tris acetate buffer (pH 8.3) at saturating concentrations of carbamoyl phosphate (4.8 mM) and subsaturating concentrations of aspartic acid (2.4 mM). Relative activity represents the ratio of activity in the absence or presence of inhibitor to that in the absence of inhibitor.

PALA, the activity decreases toward zero. The increase in activity at low PALA concentrations results from the binding of PALA, inducing the transition from the low-activity, low-affinity T state to the high-activity, high-affinity R state.⁴ Under identical conditions, PALI also activates ATCase. As seen in Figure 2, the extent of the activation induced by PALI is almost the same as PALA; furthermore, the concentration of PALI necessary to cause maximum activity is almost identical to that for PALA, indicating that the affinity of the two inhibitors for the enzyme are similar.

Small-Angle X-ray Scattering. The T and R structures of ATCase are easily distinguished by SAXS.¹⁶ To determine if the binding of PALI converts ATCase from the T to the R state, SAXS was utilized. Shown in Figure 3 are the X-ray scattering patterns of ATCase in the absence of ligands and in the presence of 2 mM PALA and 2 mM PALI. The addition of PALI caused almost the identical change in the scattering pattern as did PALA, signifying that PALI induces the allosteric transition to the R state, and the R-state structures of the enzyme in the presence of PALA or PALI are virtually identical.

Structure of the ATCase in the Presence of PALI. To better understand how PALI interacts with ATCase, the three-dimensional structure of the enzyme•PALI complex was deter-




Figure 3. Small-angle X-ray scattering of wild-type ATCase. The SAXS pattern in the absence of ligand (thick line), in the presence of 2 mM PALA (thin line), and in the presence of 2 mM PALI (dotted line). The X-ray scattering experiments were carried out in 50 mM Tris acetate buffer and 2 mM 2-mercaptoethanol and at pH 8.3.

Table 1. Data Collection and Refinement Summary of the R_{PALI} Structure^a

Data Collection	
space group	P321
resolution (Å)	30–2.3 (2.38–2.30)
total no. of reflections	435 756
no. of unique reflections	57 901
redundancy	7.53 (7.50)
completeness (%)	99.9 (100.0)
unit cell (Å)	$a = b = 120.32, c = 154.51$
angles (deg)	$\alpha = \beta = 90, \gamma = 120$
average I/σ	12.1
R_{merge}^b (%)	10.5
Refinement	
resolution (Å)	30.0–2.3
R	0.206
R_{free}	0.250
no. of waters	477
average B factor (Å ²)	38.03
RMS deviations	
bonds (Å)	0.006
angles (°)	1.31

^a Values in parentheses are for the highest resolution shell. ^b $R_{\text{merge}} = (\sum |I_{\text{hkl}} - \langle I_{\text{hkl}} \rangle|) / (\sum I_{\text{hkl}})$

mined by X-ray crystallography. Diffraction quality crystals of the enzyme•PALI complex grew to an average size of $0.3 \times 0.3 \times 0.2$ mm within one week. The R_{PALI} crystals diffracted to a maximal resolution of 2.3 Å in the P321 space group. The unit cell dimensions of these R_{PALI} crystals ($a = b = 120.32$ Å, $c = 154.51$ Å) varied slightly from the unit cell dimensions of the R_{PALA} crystals ($a = b = 122.24$ Å, $c = 156.36$ Å)¹⁷ in the same space group, see Table 1.

The quaternary conformation of the R_{PALI} structure PALI was determined using the method of Stieglitz et al.,¹⁸ which measures the vertical separation between the centers of mass of the upper and lower catalytic trimers and compares this separation to those of known T- and R-state structures. The vertical separation between the upper and the lower trimers of the R_{PALI} structure was 55.40 Å, which compares to 45.40 Å for the T_{apo} structure and 56.10 Å for the R_{PALA} structure. These results indicate that the structure of the enzyme in the presence of PALI is in the R-state conformation. The RMS deviation for both the catalytic and the regulatory chains between the R_{PALI} and R_{PALA} structures was 0.59 Å and 0.82 Å for the α -carbon and side chain atoms, respectively.

Several domain motions occur during the T-to-R transition, most notable are the movements in the 80s (residues 73–88) and 240s (residues 230–245) loops. In the T_{apo} structure, the 80s loop is positioned approximately 5 Å from the active site and is partially disordered. In the R state, the 80s loop from the adjacent catalytic chain moves approximately 5 Å into the active site, forming the catalytically competent active site.¹⁹ The structure of the 80s loop in the R_{PALI} structure is ordered, and the electron density is well-defined. In the T state, the 240s loop of C1 interacts with the 240s loop of C4 and the R4 regulatory chain, forming C1–C4 and C1–R4 interactions. In the R_{PALI} structure, the C1–C4 and C1–R4 interactions that stabilize the T state are lost.

Active Site of the R_{PALI} Structure. The active site of the R_{PALI} structure is shown in Figure 4. The electron density around PALI is well-defined and confirms the proper placement of the inhibitor in the active site. Lys84 and Ser80 from the C2 chain are in their R-state conformation interacting with PALI. The conformation of PALI is virtually identical in the C1 and C6 catalytic chains.

The positioning of PALI is similar to that of PALA in the R_{PALA} structure, see below. Residues that interact with PALI include Ser52, Thr53, Arg54, Thr55, Arg105, His134 (CP domain), Arg167, Arg229, and Gln231 (ASP domain) from the C1 catalytic chain, as well as to Ser80 and Lys84 from the adjacent C2 catalytic chain. Comparison of the C1 and C6 active sites show that the two sites are identical, with the exception of the guanidinium group of Arg54. Arg54^{NE} is shifted 1.27 Å toward the inhibitor in C6 when compared to C1 and interacts with a phosphonate oxygen atom of PALI.

Comparison of the R_{PALI} and R_{PALA} Active Sites. Figure 5 shows an overlay of the R_{PALA} and R_{PALI} structures in the active site region. A list of the hydrogen-bonding interactions and distances between the enzyme and the inhibitors, PALA and PALI, are summarized in Table 2. All residues that interact with PALA¹⁷ are also observed to interact with PALI. The binding of the PALI is very similar to that of PALA. The most noticeable difference occurs at the α -carboxylate where a hydrogen-bonding interaction between the inhibitor and Arg167^{NE} is lost in the R_{PALI} structure. In addition, a water molecule, not observed in the R_{PALA} structure, is coordinated to the nitrogen of the α -amide and Gln231^{OE1}. The volumes of the R_{PALI} and R_{PALA} active sites were determined by CASTp²⁰ and found to be similar, 323.8 Å³ and 337.9 Å³, respectively.

The interaction of PALA and PALI for their respective active sites was further investigated using the program X-Score.²¹ X-Score calculates the binding affinity of a ligand for a given enzyme of known structure. The scoring for the ligand–enzyme affinity is based on van der Waals interactions, hydrogen-bonding, deformation effect, and the hydrophobic effect. The scoring functions reveal that the van der Waals and the hydrophobic interactions are greater in the PALA•enzyme complex than the PALI•enzyme complex. However, the hydrogen-bonding contributions are greater in the enzyme•PALI complex. The scores, given in pK_d units, for the enzyme•PALA and the enzyme•PALI complex are 6.11 and 6.02, respectively. The slightly lower affinity of PALI given by X-Score is consistent with the observed K_D values determined by fluorescence.

Discussion

To reduce the charge on the known ATCase inhibitor, PALA, the α -carboxylate was converted into an amide. This modification was selected because site-specific mutagenesis experiments revealed that the removal of the side chain that interacts with




Figure 4. Stereoview of the active site with PALI bound. The $2F_o - F_c$ simulated annealing electron density map, contoured at 1.0σ , with PALI (magenta) omitted from the map calculation. The refined positions of the active site residues are overlaid onto the $2F_o - F_c$ electron density map (sky blue), contoured at 1.2σ . The hydrogen-bonding interactions between the inhibitor and the enzyme are shown as dotted lines.




Figure 5. Comparison of the structures of (a) R_{PALA} , shown in green, and (b) R_{PALI} , shown in gray. Notice the lack of a hydrogen bond between the α -amide of PALI and the guanidinium group of Arg167. The structure of the R_{PALA} enzyme was overlaid onto the R_{PALI} structure using the program SEQUIOA.³⁷

the α -carboxylate of PALA does not influence PALA binding. PALI binds remarkably similar to PALA. For example, upon the binding of PALA, or the natural substrates CP and Asp, the enzyme undergoes the T-to-R structural transition,¹³ which can be easily observed by small-angle X-ray scattering. The T-to-R transition brings the CP and ASP domains in close proximity and correctly orients catalytically important residues for catalysis.¹⁷ Small-angle X-ray scattering experiments showed that PALI can not only induce the T-to-R transition, but also the structure observed in the presence of PALI was indistinguishable from that observed in the presence of PALA. The ability of PALI to induce the T-to-R transition was functionally verified by the activation of ATCase by low concentrations of PALI at subsaturating concentrations of Asp and saturating concentrations of CP. The X-ray structure of the enzyme•PALI complex also indicates the PALI induced the T to R transition. The vertical separation between the upper and lower catalytic trimers of 55.40 Å is almost identical to that observed for the R_{PALA} structure (56.10 Å). Finally, analysis of the enzyme•PALI structure reveals that the repositioning of side chains upon the binding of PALI during the T-to-R transition is identical to that of PALA.

The structure of the ATCase in the presence of PALI was determined to investigate the exact mode of binding of the inhibitor to the enzyme. The active site of ATCase is highly

electropositive in nature. PALA binds to the enzyme through a series of hydrogen-bonding interactions, where every hydrogen-bond donor/acceptor of PALA makes at least one hydrogen-bonding interaction with the enzyme.¹⁷ PALI, with the α -carboxylate of PALA changed to an amide, loses a charged hydrogen bond between the α -carboxylate of PALI and the side chain of Arg167. The loss of a single hydrogen bond between a charged acceptor and an uncharged donor should account for approximately 4 kcal/mol of binding energy, whereas the loss of a noncharged hydrogen bond should account for approximately 0.5–1.5 kcal/mol of binding energy.^{22,23} Counting the hydrogen-bonding interactions of the R_{PALI} structure reveals 22 hydrogen bonds as opposed to the R_{PALA} structure that contains 21 hydrogen bonds. The loss of the charged hydrogen bond to the α -carboxylate of PALI leads to a 2.7-fold reduction in the binding affinity.

A mutant version of ATCase, R167Q, has been characterized in our laboratory.²⁴ Arg167 makes two hydrogen bonds with the α -carboxylate in PALA and the tetrahedral intermediate,¹⁷ neutralizing the negative charge on the carboxylate. The mutation of Arg167 to Gln results in an enzyme with reduced activity, yet there is no alteration in the binding affinities for Asp or PALA. Upon mutation of Arg167 to glutamine, one hydrogen bond is lost between the enzyme and the negatively charged α -carboxylate of PALA (or Asp). However, a charged—

Table 2. Hydrogen Bond Distances between PALA/PALI and the Active Site Residues of ATCase

residue	atom	inhibitor atom	PALA distance (Å)	PALI distance (Å)
Ser52	OG	OP3	2.52	2.69
Thr53	N	OP2	2.81	2.80
Arg54	N	OP2	3.08	2.95
Arg54	NH1	OP2	3.21	2.36
Thr55	N	OP3	2.76	2.83
Thr55	OG1	OP3	2.71	2.64
Thr55	OG1	O1	3.14	2.97
Arg105	NH1	OP3	3.28	3.25
Arg105	NH1	OP1	2.58	2.77
Arg105	NH2	O1	2.67	2.83
His134	NE2	O1	2.51	2.77
Arg167	NE	O2	2.71	
Arg167	NH2	O3	3.00	2.80
Arg229	NE	O5	2.68	2.78
Arg229	NH2	O4	2.89	2.91
Arg229	NH2	O5		3.24
Gln231	NE2	O5	3.11	3.22
Leu267	O	N2	3.06	2.68
Ser80	OG	OP2	2.91	2.65
Ser80	OG	OP1		3.08
Lys84	NZ	OP1	3.02	2.85
Lys84	NZ	O3	3.08	3.06
Lys84	NZ	O4	3.00	2.60

uncharged hydrogen bond at position 167 between the amide nitrogen and the carboxylic acid still exists. In the case of PALI, the replacement of the negatively charged α -carboxylate with an amide leads to a loss of a charged hydrogen bond between the enzyme and the PALI. As a result, the affinity of PALI is decreased due to the loss of the charged hydrogen bond, unlike the loss of the uncharged hydrogen bond in the case of R167Q.

If the difference in binding were solely related to the loss of a hydrogen bond between a charged hydrogen-bond acceptor and an uncharged hydrogen-bond donor, the ΔG between the two inhibitors should be approximately 4 kcal/mol. However, the difference in ΔG between PALA and PALI is only 1.0 kcal/mol. In the R_{PALI} structure, the presence of two additional hydrogen bonds adds approximately 1.5 kcal/mol of binding energy, per hydrogen bond, to the enzyme–inhibitor complex. In addition, four hydrogen bonds in the R_{PALI} are shorter than in the R_{PALA} by at least 0.25 Å, potentially leading to stronger hydrogen-bonding interactions. The increased hydrogen bonding compensates for the loss of the charged hydrogen bond between Arg167 and the α -carboxylate of PALA. In addition, the X-Score results support the conclusion that the hydrogen-bonding interactions in the enzyme•PALI complex are greater than the PALA enzyme complex, resulting in a 2-fold loss of binding affinity of PALI for the active site of ATCase.

In this report, we characterize the binding of a new potent inhibitor of ATCase, PALI, using fluorescence, SAXS, and X-ray crystallography. Even though PALI has less charge than PALA, PALI still binds with high affinity. The binding of PALI induces the T-to-R transition of ATCase and is able to convert unoccupied active sites into their high-activity high-affinity functional state. The X-ray structure of the enzyme•PALI complex reveals that residues in the active site rearrange to form the catalytically active enzyme. These conformational changes afford high-affinity binding for the inhibitor to the enzyme. PALI can induce the allosteric transition even though there is the loss of a charged hydrogen-bonding interaction between the enzyme and the inhibitor. The loss of this charge is not detrimental to the activity of PALI due to additional hydrogen-bonding interactions between the enzyme–inhibitor complex. The kinetic characterization and crystal structure of the ATCase•

PALI complex also provides detailed information regarding the importance of the α -carboxylate for the binding of both PALA and the substrate aspartate.

Experimental Procedures

Materials. L-Aspartate, *N*-carbamoyl-L-aspartate, potassium dihydrogen phosphate, sodium azide, and uracil were obtained from Sigma Chemical Co. (St. Louis, Missouri). Tris was purchased from ICN (Costa Mesa, California). Dialysis buttons (50 μ L) and Aqua Sil were purchased from Hampton Research. Dialysis buttons were siliconized according to the supplier's instructions. All commercially available starting materials and solvents were reagent grade or better and used without further purification. Thin-layer chromatography was performed on Merck silica gel 60 plates with fluorescent indicator, and column chromatography was carried out on silica gel purchased from Fisher Scientific.

Enzyme Preparation. Wild-type *E. coli* ATCase and the C47A/A241C mutant ATCase were expressed and purified as described previously.²⁵ The C47A/A241C enzyme was labeled with pyrene as previously described.¹⁵ The concentration of the purified holoenzyme was determined by absorption at 280 nm with an extinction coefficient of 0.59 cm²/mg or by using the Bio-Rad version of Bradford's dye binding assay²⁶ using wild-type ATCase as the standard. The purity of the enzyme was determined using SDS-PAGE²⁷ and nondenaturing PAGE.^{28,29}

Preparation of β -Benzyl *N*-tert-Butoxycarbonyl-L-aspartate (3).³⁰ To a stirred solution of β -benzyl L-aspartate (2; 4.46 g, 20 mmol) and sodium bicarbonate (3.36 g, 40 mmol) in 60 mL water, di-*tert*-butyl dicarbonate (5.89 g, 27 mmol) in 60 mL THF was added at 0 °C, and the reaction mixture was stirred overnight at room temperature. After the completion of the reaction, THF was removed by distillation under reduced pressure, and the residue was extracted with ethyl acetate after acidifying the mixture using 10% citric acid. The organic layer was washed with brine and water and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford β -benzyl *N*-tert-butoxycarbonyl-L-aspartate (3) in quantitative yield. This crude material was used for the next reaction step without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.36 (s, 9H), 2.59 (dd, *J* = 7.4 Hz, 15.0 Hz, 1H), 2.72 (dd, *J* = 6.0 Hz, 15.2 Hz, 1H), 4.05 (m, 1H), 5.05 (m, 2H), 6.46 (d, *J* = 6.8 Hz, 1H), 7.29–7.38 (m, 5H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 28.23, 37.74, 51.68, 65.23, 77.60, 127.52, 127.60, 128.13, 136.14, 154.70, 170.70, 172.45; ESI-MS (*m/z*) 346.0 [M + Na]⁺

Preparation of β -Benzyl *N*-tert-Butoxycarbonyl-L-isoasparaginate (4).³¹ To a solution of β -benzyl *N*-tert-butoxycarbonyl-L-aspartate (6.5 g, 20 mmol) and triethylamine (2.06, 20.4 mmol) in a mixture of anhydrous dichloromethane (100 mL) and dioxane (120 mL), ethyl chloroformate (2.4 g, 20.4 mmol) was added at –5 to –10 °C and the mixture was stirred at this temperature for 30 min. Then 6 mL of a 28% aqueous ammonia solution was added to the reaction and the mixture stirred for 4 h at room temperature. The reaction mixture was then poured into 100 mL of dichloromethane, and the mixture was washed with hydrochloric acid (0.5 N, 3 \times 50 mL). The organic layer was separated, washed with water, and concentrated under reduced pressure to give crude product. The crude product was further purified by precipitation from a mixture of ethyl acetate–hexane. Yield 5.56 g (86%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.37 (s, 9H), 2.57 (dd, *J* = 8.6 Hz, 16.2 Hz, 1H), 2.75 (dd, *J* = 5.4 Hz, 15.8 Hz, 1H), 4.25–4.31 (m, 1H), 5.05–5.12 (m, 2H), 7.04 (d, *J* = 8.4 Hz, 1H), 7.10 (s, br, 1H), 7.27 (s, br, 1H), 7.31–7.37 (m, 5H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 28.19, 36.40, 50.80, 65.49, 78.14, 93.80, 127.54, 127.71, 128.15, 135.87, 154.87, 169.95, 172.30; ESI-MS (*m/z*) 345.0 [M + Na]⁺

Preparation of β -Benzyl L-Isoasparaginate (5).³¹ To a solution of β -benzyl *N*-tert-butoxycarbonyl-L-isoasparaginate (537 mg, 1.67 mmol) in 10 mL of dichloromethane, 10 mL of trifluoroacetic acid was added at 0 °C and the mixture was stirred for 4 h at room temperature. The solvent and TFA were removed by distillation

under reduced pressure, and the residue obtained was triturated with anhydrous diethyl ether. The precipitate was dried under nitrogen to afford β -benzyl L-isoasparagine (**5**) as the trifluoroacetic acid salt. Yield = 505 mg (90%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 2.89 (dd, $J = 7.8$ Hz, 17.4 Hz, 1H), 3.0 (dd, $J = 4.4$ Hz, 17.2 Hz, 1H), 4.05–4.08 (m, 1H), 5.12–5.19 (m, 2H), 7.34–7.40 (m, 5H), 7.65 (s, br, 1H), 7.87 (s, br, 1H), 8.2 (s, br, 3H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 35.22, 48.76, 66.24, 127.90, 128.00, 128.27, 135.45, 168.77, 168.92; ESI-MS (m/z) 245.09 [$\text{M} + \text{Na}$] $^+$

Preparation of β -Benzyl *N*-Chloroacetyl-L-isoasparaginate (6**).** To a mixture of β -benzyl L-isoasparaginate trifluoroacetic acid salt (5.12 g, 15 mmol) and pyridine (6.05 mL, 75 mmol) in 125 mL anhydrous dichloromethane, chloroacetic anhydride (5.65 g, 33 mmol) was added portion-wise, while keeping the temperature at 0 °C. After the addition was complete, the reaction mixture was stirred for 4 h at room temperature. Then the mixture was washed with water (2×50 mL), saturated sodium bicarbonate (3×50 mL), and again with water (1×50 mL). The organic layer was collected, dried over Na_2SO_4 , and concentrated under reduced pressure to afford the crude product. This was purified by repeated precipitation using hexane on a saturated solution of crude mixture in dichloromethane. Yield = 3.6 g (80%). ^1H NMR (400 MHz, CDCl_3) δ 2.73 (dd, $J = 6.8$ Hz, 17.2 Hz, 1H), 3.07 (dd, $J = 4.0$ Hz, 17.2 Hz, 1H), 4.02–4.10 (m, 2H), 4.81–4.86 (m, 1H), 5.17 (s, 2H), 5.51 (s, br, 1H), 6.45 (s, br, 1H), 7.33–7.40 (m, 5H), 7.85 (d, $J = 6.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 35.87, 42.63, 49.40, 67.38, 128.43, 128.61, 128.72, 135.15, 166.34, 171.51, 171.64; ESI-MS (m/z) 320.9 [$\text{M} + \text{Na}$] $^+$

Preparation of β -Benzyl *N*-(Diethoxyphosphinoyl)acetyl-L-isoasparaginate (7**).** A mixture of β -benzyl *N*-chloroacetyl-L-isoasparaginate (3.6 g, 12 mmol) and triethyl phosphite (20 mL) were heated at 150 °C for 8 h and then excess triethyl phosphite was removed by distillation under reduced pressure to give crude product as a colorless viscous liquid. The pure product (**7**) was obtained by silica column chromatography using a mixture of ethyl acetate/methanol (9.5:0.5). Yield = 4.6 g (95%). ^1H NMR (400 MHz, CDCl_3) δ 1.33 (t, $J = 7.0$ Hz, 6H), 2.76–3.02 (m, 3H), 3.11 (dd, $J = 5.4$ Hz, 17.4 Hz, 1H), 4.09–4.19 (m, 4H), 4.93–4.98 (m, 1H), 5.07–5.14 (m, 2H), 6.21 (s, br, 1H), 7.28–7.32 (m, 5H), 7.50 (s, br, 1H), 7.62 (d, $J = 9.2$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 16.63, 35.74, 36.22 (d, $J_{\text{CP}} = 127$ Hz), 49.30, 62.97, 63.75, 66.98, 128.26, 128.37, 128.61, 135.48, 164.22, 171.59, 173.22; ^{31}P NMR (121 MHz, CDCl_3) δ 22.77; ESI-MS (m/z) 423.13 [$\text{M} + \text{Na}$] $^+$. Anal. ($\text{C}_{17}\text{H}_{25}\text{N}_2\text{O}_7\text{P}$), C, H, N.

Preparation of β -Benzyl *N*-Phosphonacetyl-L-isoasparaginate (8**).** To a solution of β -benzyl *N*-(diethoxyphosphinoyl)acetyl-L-isoasparaginate (400 mg, 1 mmol) in anhydrous acetonitrile (10 mL), trimethylsilyl bromide was added (560 mL, 5.6 mmol) at 0 °C and then the mixture was stirred overnight at room temperature. The solvents were evaporated under vacuum and 5 mL of water was added. The mixture was stirred for 1 h at room temperature, washed with dichloromethane, and lyophilized to give pure product **8** in quantitative yield. ^1H NMR (400 MHz, D_2O) δ 2.62–2.78 (m, 2H), 2.85 (dd, $J = 8.2$ Hz, 16.6 Hz, 1H), 2.95 (dd, $J = 5.1$ Hz, 16.4 Hz, 1H), 4.72 (m, 1H), 5.15–5.37 (m, 2H), 7.36–7.40 (m, 5H); ^{31}P NMR (121 MHz, D_2O) δ 15.98; ESI-MS (m/z) 367.06 [$\text{M} + \text{Na}$] $^+$

Preparation of *N*-Phosphonacetyl-L-isoasparagine (1**).** To a solution of β -benzyl *N*-phosphonacetyl-L-isoasparaginate (275 mg, 0.8 mmol) in THF/ethanol (25 mL/15 mL) was added 10% Pd/C (132 mg), and the mixture was stirred overnight under a hydrogen atmosphere. After the completion of the reaction, Pd was removed by filtration and the filtrate was concentrated under reduced pressure to give a viscous colorless liquid. This was dissolved in 10 mL water and washed with dichloromethane, and the aqueous phase was lyophilized to give pure product **1** as a hygroscopic solid. Yield = 186 mg (92%). ^1H NMR (400 MHz, D_2O) δ 2.78–2.99 (m, 4H), 4.72–4.79 (m, 1H); ^{31}P NMR (121 MHz, D_2O) δ 17.95; ESI-MS (m/z) 253.02 [$\text{M} - \text{H}$] $^-$. Anal. ($\text{C}_6\text{H}_{11}\text{N}_2\text{O}_7\text{P} \cdot \text{H}_2\text{O} \cdot 0.3\text{EtOH}$), C, H, N.

Methods

Synthesis. All moisture-sensitive reactions were performed under a nitrogen atmosphere with oven-dried glassware.

Characterization. ^1H and ^{13}C NMR spectra were recorded on a Varian 400 or 300 spectrometer. Proton chemical shifts are reported in ppm (δ) relative to internal tetramethylsilane (TMS, δ 0.0) or with the solvent reference relative to TMS employed as the internal standard (CDCl_3 , δ 7.26 ppm; $\text{DMSO}-d_6$, δ 2.50). Data reported as follows: chemical shift (multiplicity [singlet (s), doublet (d), triplet (t), and multiplet (m)], coupling constants [Hz], integration). ^{13}C NMR spectra were recorded on a Varian 400 (100 MHz) spectrometer with complete proton decoupling. The chemical shifts were reported relative to CDCl_3 (77.0 ppm) or $\text{DMSO}-d_6$ (39.52 ppm) for solutions in CDCl_3 and $\text{DMSO}-d_6$, respectively. ^{31}P NMR spectra were recorded on a Varian 300 (121 MHz) spectrometer using 85% H_3PO_4 as an external standard. Mass spectra were obtained at the Mass Spectrometry Facilities of Boston College.

Fluorescence Measurements. Fluorescence emission spectra were recorded at 20 ± 1 °C in 50 mM Tris acetate buffer, pH 8.3, on a Jasco FP-6300 spectrofluorometer using pyrene-labeled ATCase. The excitation wavelength was 338 nm; emission spectra were collected between 360 and 560 nm; and the excitation and emission bandwidths were set to 5 nm. To approximate the degree of quaternary structure change for the enzyme, the intensity of the fluorescence signal F_T at 377 nm was measured as the population of T-state enzyme.¹⁵ Saturation curves were determined by the incremental addition of PALA or PALI to the pyrene-labeled ATCase (1 mM enzyme) until there was no further change in fluorescence. The data were normalized by dividing each data point by F_T in the absence of ligand.

Small-Angle X-ray Scattering. Small-angle X-ray scattering curves were collected for the wild-type holoenzyme in the absence of ligands and in the presence of PALA or PALI, according to Stieglitz et al.³² Solution X-ray scattering experiments were conducted at the Beam Line 4-2, at the Stanford Synchrotron Radiation Laboratory, Menlo Park, CA.

Crystallization and Freezing of Crystals. The purified enzyme was crystallized by microdialysis, using 50 μL wells. The enzyme solution, at 18 mg/mL, was dialyzed against the crystallization buffer, which consisted of 50 mM maleic acid, 1 mM PALI, and 3 mM sodium azide at pH 5.7. Crystals formed within 3 days, with average dimensions of $0.3 \times 0.3 \times 0.2$ mm. Crystals were soaked in a solution of 30% 2-methyl-2,4-pentanediol in crystallization buffer for approximately 1 min prior to freezing in liquid nitrogen.

X-ray Data Collection and Processing. The diffraction data were collected using a Rigaku/MSR R-axis IV++ detector while X-rays were generated using a Rigaku/MSR RU-200 rotating-anode generator operating at 50 kV and 100 mA at the Boston College Crystallographic Facility. The diffraction data, collected to 2.3 Å, were integrated, scaled, and averaged using the program d*TREK (Rigaku/MSR).³³

Structural Refinement. The data were refined using the coordinates of wild-type *E. coli* ATCase complexed with PALA (PDB entry 1DO9), as the initial model.¹⁷ Prior to refinement, all waters and ligands were removed. The structure was refined using CNS,³⁴ and refinement statistics are summarized in Table 1. Initially rigid body refinement was carried out followed by simulated annealing. After rigid body, simulated annealing, energy minimization, and B-factor refinement initial maps were analyzed. Trouble areas of the structure, the N-termini of the regulatory chains (residues 1–11), the 50s loop of the regulatory chains, and residues 65–72 of the R6 regulatory chain were manually rebuilt using XtalView.³⁵ The N-termini of the regulatory chains were highly disordered even after several rounds of rebuilding, therefore, residues 1–9 of the regulatory chains were omitted from the structure. After rebuilding was complete, PALI was fit into the $F_o - F_c$ electron density. Placement of the PALI was verified using simulated annealing omit maps.

Waters were added to the structure using CNS and XtalView on the basis of the $F_o - F_c$ electron density maps at or above the 2.8 σ

level. Waters were checked and retained only when they were able to form hydrogen bonds. The model was checked for errors using PROCHECK.³⁶ The details of the data processing and refinement are given in Table 1.

Acknowledgment. This work was supported by Grant GM26237 from the National Institutes of Health. The Stanford Synchrotron Radiation Laboratory (SSRL) is operated by the Department of Energy, Office of Basic Energy Sciences. The SSRL Structural Biology Resource is supported by the National Institutes of Health, National Center for Research Resources (P41RR01209), and by the Department of Energy, Office of Biological and Environmental Research.

References

- Hsuanyu, Y.; Wedler, F. C. Kinetic mechanism of native *Escherichia coli* aspartate transcarbamoylase. *Arch. Biochem. Biophys.* **1987**, *259*, 316–330.
- Gerhart, J. C.; Pardee, A. B. Enzymology of control by feedback inhibition. *J. Biol. Chem.* **1962**, *237*, 891–896.
- Wild, J. R.; Loughrey-Chen, S. J.; Corder, T. S. In the presence of CTP, UTP becomes an allosteric inhibitor of aspartate transcarbamoylase. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 46–50.
- Collins, K. D.; Stark, G. R. Aspartate transcarbamoylase: Interaction with the transition state analogue *N*-(phosphonacetyl)-L-aspartate. *J. Biol. Chem.* **1971**, *246*, 6599–6605.
- Yoshida, T.; Stark, G. R.; Hoogenraad, J. Inhibition by *N*-(phosphonacetyl)-L-aspartate of aspartate transcarbamoylase activity and drug-induced cell proliferation in mice. *J. Biol. Chem.* **1974**, *249*, 6951–6955.
- Tsuboi, K. K.; Edmunds, H. N.; Linda, K. Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells. *Cancer Res.* **1977**, *37*, 3080–3087.
- Johnson, R. K.; Inouye, T.; Goldin, A.; Stark, G. R. Antitumor activity of *N*-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamoylase. *Cancer Res.* **1976**, *36*, 2720–2725.
- Pfund, E.; Lequeux, T.; Masson, S.; Vazeux, M.; Cordi, A.; Pierre, A.; Serre, V.; Herve, G. Efficient synthesis of fluorothiosparfosic acid analogues with potential antitumoral activity. *Bioorg. Med. Chem.* **2005**, *13*, 4921–4928.
- Lindell, S. D.; Turner, R. M. Synthesis of potential inhibitors of the enzyme aspartate transcarbamoylase. *Tetrahedron Lett.* **1990**, *31*, 5381–5384.
- Kim, J.-S.; Heath, T. D. Antitumor efficacy of liposomal *N*-(phosphonacetyl)-L-aspartic acid in C-26 tumor bearing Balb/c mice. *Yakche Hakhoechi* **2000**, *30*, 39–45.
- Kim, J.-S.; Heath, T. D. Therapeutic potency of *N*-(phosphonacetyl)-L-aspartic acid in liposome in established tumor bearing mice. *Yakche Hakhoechi* **2000**, *30*, 127–131.
- Ke, H.-M.; Lipscomb, W. N.; Cho, Y.; Honzatko, R. B. Complex of *N*-phosphonacetyl-L-aspartate with aspartate carbamoyltransferase: X-ray refinement, analysis of conformational changes and catalytic and allosteric mechanisms. *J. Mol. Biol.* **1988**, *204*, 725–747.
- Fetler, L.; Tauc, P.; Vachette, P. Carbamyl phosphate modifies the T quaternary structure of aspartate transcarbamoylase, thereby facilitating the structural transition associated with cooperativity. *J. Appl. Crystallogr.* **1997**, *30*, 781–786.
- Wang, J.; Stieglitz, K. A.; Cardia, J. P.; Kantrowitz, E. R. Structural basis for ordered substrate binding and cooperativity in aspartate transcarbamoylase. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 8881–8886.
- West, J. M.; Tsuruta, H.; Kantrowitz, E. R. A Fluorescent Probe-Labeled Aspartate Transcarbamoylase that Monitors the Allosteric Conformational State. *J. Biol. Chem.* **2004**, *279*, 945–951.
- Hervé, G.; Moody, M. F.; Tauc, P.; Vachette, P.; Jones, P. T. Quaternary structure changes in aspartate transcarbamoylase studied by X-ray solution scattering: signal transmission following effector binding. *J. Mol. Biol.* **1985**, *185*, 189–199.
- Jin, L.; Stec, B.; Lipscomb, W. N.; Kantrowitz, E. R. Insights into the mechanism of catalysis and heterotropic regulation of *E. coli* aspartate transcarbamoylase based upon a structure of enzyme complexed with the bisubstrate analogue *N*-phosphonacetyl-L-aspartate at 2.1 Å. *Proteins: Struct. Funct. Genet.* **1999**, *37*, 729–742.
- Stieglitz, K.; Stec, B.; Baker, D. P.; Kantrowitz, E. R. Monitoring the transition from the T to the R state in *E. coli* aspartate transcarbamoylase by X-ray crystallography: Crystal structures of the E50A mutant in four distinct allosteric states. *J. Mol. Biol.* **2004**, *341*, 853–868.
- Krause, K. L.; Voltz, K. W.; Lipscomb, W. N. Structure at 2.9-Å resolution of aspartate carbamoyltransferase complexed with the bisubstrate analogue *N*-(phosphonacetyl)-L-aspartate. *Proc. Natl. Acad. Sci. U.S.A.* **1985**, *82*, 1643–1647.
- Liang, J.; Edelsbrunner, H.; Woodward, C. Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. *Protein Sci.* **1998**, *7*, 1884–1897.
- Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. *J. Comput.-Aided Mol. Des.* **2002**, *16*, 11–26.
- Street, I. P.; Armstrong, C. R.; Withers, S. G. Hydrogen bonding and specificity. Fluoro-deoxy sugars as probes of hydrogen bonding in the glycogen phosphorylase-glucose complex. *Biochemistry* **1986**, *25*, 6021–6027.
- Fersht, A. The hydrogen bonding in molecular recognition. *TIBS* **1987**, *12*, 301–304.
- Stebbins, J. W.; Zhang, Y.; Kantrowitz, E. R. The importance of residues Arg-167 and Gln-231 in both the allosteric and catalytic mechanisms of *Escherichia coli* aspartate transcarbamoylase. *Biochemistry* **1990**, *29*, 3821–3827.
- Nowlan, S. F.; Kantrowitz, E. R. Superproduction and rapid purification of *E. coli* aspartate transcarbamoylase and its catalytic subunit under extreme derepression of the pyrimidine pathway. *J. Biol. Chem.* **1985**, *260*, 14712–14716.
- Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **1976**, *72*, 248–254.
- Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **1970**, *227*, 680–685.
- Davis, B. J. Disc electrophoresis-II Method and application to human serum proteins. *Ann. N.Y. Acad. Sci.* **1964**, *121*, 404–427.
- Ornstein, L. Disc Electrophoresis. I. Background And Theory. *Ann. N.Y. Acad. Sci.* **1964**, *121*, 321–349.
- Asano, Y.; Umezaki, M.; Li, Y.-F.; Tsubota, S.; Lubbehusen, T. L. Isolation of microorganisms which utilize acidic D-amino acid oligomers. *J. Mol. Catal. B: Enzym.* **2001**, *12*, 53–59.
- Ariyoshi, Y.; Shiba, T.; Kaneko, T. Synthetic studies of bacitracin. II. Synthesis of a cyclic dodecapeptide, an analogue of bacitracin A. *Bull. Chem. Soc. Jpn.* **1967**, *40*, 2648–2654.
- Stieglitz, K. A.; Dusinger, K. J.; Cardia, J. P.; Tsuruta, H.; Kantrowitz, E. R. Structure of the *E. coli* Aspartate Transcarbamoylase Trapped in the Middle of the Catalytic Cycle. *J. Mol. Biol.* **2005**, *352*, 478–486.
- Pflugrath, J. W. The finer things in X-ray diffraction data collection. *Acta Crystallogr.* **1999**, *D55*, 1718–1725.
- Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, N.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography and NMR system (CNS): A new software system for macromolecular structure determination. *Acta Crystallogr.* **1998**, *D54*, 905–921.
- McRee, D. E. XtalView/Xfit—A versatile program for manipulating atomic coordinates and electron density. *J. Struct. Biol.* **1999**, *125*, 156–165.
- Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: A program to check the stereochemical quality of protein structures. *J. Appl. Crystallogr.* **1993**, *26*, 283–291.
- Bruns, C. M.; Hubatsch, I.; Ridderstrom, M.; Mannervik, B.; Tainer, J. A. Human glutathione transferase A4-4 crystal structures and mutagenesis reveal the basis of high catalytic efficiency with toxic lipid peroxidation products. *J. Mol. Biol.* **1999**, *288*, 427–439.

JM0607294